Company intelligence / Profile preview

Zinfandel Pharmaceuticals, Inc.

Durham, North Carolina, United Statestakeda.com ↗

Ownership: Private
Employees: ~8
Development stage: Phase 3

Overview

The Phase III TOMMORROW trial was terminated in January 2018 following a planned futility analysis that showed inadequate treatment effect with pioglitazone 0.8 mg SR in delaying the onset of mild cognitive impairment due to Alzheimer's disease[2][8].

Therapeutic areas: Neurology
Modalities: Small molecules (pioglitazone)
Industry: Biotech

Drug pipeline

1 asset

pioglitazone

Phase 3

Indications: Alzheimer's disease

Partnerships

Takeda Pharmaceutical Company Limited

Beyond the preview

Go deeper on Zinfandel Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zinfandel Pharmaceuticals, Inc..

Explore the full profile